Comparative evaluation between the genotypic and phenotypic methods for detection of drug-resistant Mycobacterium tuberculosis
DOI:
https://doi.org/10.61529/idjp.v34i3.455Abstract
Background: Tuberculosis (TB) is one of the major health problems with significant morbidity and mortality worldwide. According to world health organization in 2020 published guidelines for diagnosis and treatment of TB. To compare between genotypic and phenotypic methods for detection of drug resistant Mycobacterium tuberculosis.
Material and Methods: This cross-sectional validation study was conducted from January to September 2024 in BSL-3 laboratories of Islamabad Diagnostic Center, Izzat Ali Shah Hospital, and POF Hospital Wah Cantt, Pakistan. A total of 87 culture-positive Mycobacterium tuberculosis (MTB) isolates were tested for susceptibility to Rifampicin, Isoniazid, Ethambutol, and Streptomycin using the MGIT 960 system and GeneXpert. DNA was extracted with the Gentra System kit, and multiplex PCR targeting rpoB, katG, and embB genes was performed. Gel electrophoresis was used to compare banding patterns of MDR and XDR MTB.
Results: Out of 87 MTB samples 4 were multidrug resistant (MDR) and 30 were Single drug resistant (SDR). Among single drug resistant 2 were Rifampicin resistant, 24 were isoniazid resistant ,3 were ethambutol resistant. 3 samples use control (negative, positive and normal) non-MTB samples. and 50 samples were detected as MOTTS, The Sensitivity, Specificity, PPV, NPV and DA of MDR, Rifampicin, Isoniazid and Ethambutol were66.67%, 100.00%,33.33%, 71.43%,66.67%, 100.00%, 100.00%, 50.00%, 75.00%,85.71%,80.00%,96.00%, 50.00%,84.50%, ,100.00%, 50.00%,75.00%, 100.00%and 80.00% respectively genotypically by (multiplex PCR).
Conclusion; In this study genotypic methods for detection of drug resistant MTB were rapid as compare to phenotypic methods for timely and active management.
Keywords: Genotypic, Mycobacterium tuberculosis, Phenotypic.
References
Mirzayev F, Viney K, Linh NN, Gonzalez-Angulo L, Gegia M, Jaramillo E, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57(6): 2003300. DOI: https://doi.org/10.1183/13993003.03300-2020
Behr MA, Kaufmann E, Duffin J, Edelstein PH, Ramakrishnan L. Latent tuberculosis: Two centuries of confusion. Am J Respir Crit Care Med. 2021; 204(2): 142-8. DOI: https://doi.org/10.1164/rccm.202011-4239pp
Houben RM, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health. 2016; 4(11): e806-e15. DOI: https://doi.org/10.1016/s2214-109x(16)30199-1
Bagcchi S. WHO's global tuberculosis report 2022. Lancet Microbe. 2023; 4(1): e20. DOI: https://doi.org/10.1016/s2666-5247(22)00359-7
Aftab A, Afzal S, Qamar Z, Idrees M. Early detection of MDR Mycobacterium tuberculosis mutations in Pakistan. Sci Rep. 2021; 11(1): 16736. DOI: https://doi.org/10.1038/s41598-021-96116-x
Lewinsohn DM, Lewinsohn DA. New concepts in tuberculosis host defense. Clin Chest Med. 2019; 40(4): 703-19. DOI: https://doi.org/10.1016/j.ccm.2019.07.002
Verma AK, Yadav RN, Kumar G, Dewan RK. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains in geriatrics: An analysis and its implications in tuberculosis control. J Clin Tuberc Other Mycobact Dis. 2022; 27: 100317. DOI: https://doi.org/10.1016/j.jctube.2022.100317
Bernardo J. Diagnosis of pulmonary tuberculosis in adults. UpToDate Last updated: 29th August 2025. Available from: http://112.2.34.14:9095/contents/diagnosis-of-pulm onary-tuberculosis-in-adults
Jain S, Agrawal R. Rapid Diagnosis of pulmonary and extrapulmonary tuberculosis by cartridge-based nucleic acid amplification test (CBNAAT). IP Int J Med Microbiol Tropl Dis 2019; 5(4): 204–6. DOI: https://doi.org/10.18231/j.ijmmtd.2019.046
Zaporojan N, Hodișan R, Pantiș C, Csep AN, Zaporojan C, Zaha DC. Genotypic and phenotypic methods in the detection of MDR-TB and evolution to XDR-TB. Antibiotics (Basel). 2025; 14(7): 732. DOI: https://doi.org/10.3390/antibiotics14070732
Wen X-H, Han Y-L, Cao X-S, Zhao W, Yan Z, Yan L, et al. Diagnostic value of nucleic acid amplification tests for tuberculous pleural effusion. Future Microbiol. 2023; 18(14): 971-83. DOI: https://doi.org/10.2217/fmb-2023-0025
De Maio F, Cingolani A, Bianco DM, Salustri A, Palucci I, Sanguinetti M, et al. First description of the katG gene deletion in a Mycobacterium tuberculosis clinical isolate and its impact on the mycobacterial fitness. Int J Med Microbiol. 2021; 311(4): 151506. DOI: https://doi.org/10.1016/j.ijmm.2021.151506
Gausi K, Ignatius EH, De Jager V, Upton C, Kim S, McKhann A, et al. High-Dose isoniazid lacks EARLY bactericidal activity against isoniazid-resistant tuberculosis mediated by katG mutations: A randomized phase II clinical trial. Am J Respir Crit Care Med. 2024; 210(3): 343-51. DOI: https://doi.org/10.1164/rccm.202311-2004oc
Seid A, Berhane N, Nureddin S. Frequency of rpoB, katG, and inhA gene polymorphisms associated with multidrug‐resistant Mycobacterium tuberculosis complex isolates among Ethiopian TB patients: A systematic review. Interdiscip Perspect Infect Dis. 2022; 2022(1): 1967675. DOI: https://doi.org/10.1155/2022/1967675
Huang YY, Li X, Wu YF, Jia QJ, Cheng QL, Li QC, et al. Characterization of mutations in genes related to rifampicin and isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis strains from Hangzhou, China. Biomed Environ Sci. 2023;36(9): 869-73. DOI: https://doi.org/10.3967/bes2023.112
Bruno L, Ahava M, Janne A, Terhi ML, Anu PS. Diagnostic performance of Xpert MTB/RIF Ultra assay with pulmonary and extrapulmonary specimens: a retrospective evaluation in a low-incidence setting in Finland. Clin Microbiol Infect. 2025: S1198-743X(25)00452-5. DOI: https://doi.org/10.1016/j.cmi.2025.09.002
Rindi L, Puglisi V, Franconi I, Lupetti A. Comparison between Xpert ultra and standard M10 for detection of MTBC in clinical samples. Diagn Microbiol Infect Dis. 2025; 114(1): 117102. DOI: https://doi.org/10.1016/j.diagmicrobio.2025.117102
Zhang R, Bao X, Bao F, Teng C, Xu D, Liu Z, et al. Evaluation of the Xpert MTB/XDR test for detection of isoniazid, fluoroquinolones, and second-line injectable drugs resistance to Mycobacterium tuberculosis-Anhui Province, China. PLoS One. 2025; 20(9): e0331264. DOI: https://doi.org/10.1371/journal.pone.0331264
Zhao Y, Du L, Song J, Sun W, Chen Y, Yu X, et al. Hierarchical integration of mNGS, PCR, and other conventional methods for precision TB diagnostics. Microbiol Spectr. 2025: e0193125. DOI: https://doi.org/10.1128/spectrum.01931-25
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Dr Saira
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
